- Home
- SNOA vs APRE Comparison
SNOA vs APRE Comparison
Compare SNOA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNOA | APRE |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.9M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNOA | APRE |
|---|---|---|
| Price | $3.72 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 22.2K | ★ 71.8K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,937,000.00 | $488,239.00 |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $24.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.02 | N/A |
| 52 Week Low | $1.75 | $0.90 |
| 52 Week High | $6.92 | $5.00 |
Technical Indicators
Market Signals| Indicator | SNOA | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 30.90 |
| Support Level | $3.45 | $0.90 |
| Resistance Level | $3.95 | $1.14 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 55.56 | 8.98 |
Price Performance
Historical ComparisonAbout SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.